Organigram - OGI Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organigram in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OGI shares.
View OGI analyst ratings or view top-rated stocks.

2 brokerages have issued twelve-month price targets for Organigram's stock. Their OGI share price forecasts range from $1.50 to $2.00. On average, they predict the company's share price to reach $1.67 in the next year. This suggests a possible upside of 160.4% from the stock's current price.
View analysts price targets for OGI or view top-rated stocks among Wall Street analysts.

Organigram's stock was trading at $0.80 at the start of the year. Since then, OGI stock has decreased by 20.0% and is now trading at $0.64.
View the best growth stocks for 2023 here.

Organigram saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 6,670,000 shares, an increase of 23.7% from the February 13th total of 5,390,000 shares. Based on an average trading volume of 1,170,000 shares, the days-to-cover ratio is presently 5.7 days.
View Organigram's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 11th 2023.
View our OGI earnings forecast.

Organigram Holdings Inc. (NASDAQ:OGI) issued its quarterly earnings results on Thursday, January, 12th. The company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). The company earned $32.16 million during the quarter, compared to analyst estimates of $32.63 million. Organigram had a negative net margin of 4.97% and a negative trailing twelve-month return on equity of 6.00%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Organigram investors own include KushCo (KSHB), Auxly Cannabis Group (CBWTF), Supreme Cannabis (SPRWF), Medical Marijuana (MJNA), CNBX Pharmaceuticals (CNBX), MariMed (MRMD), Aurora Cannabis (ACB), EVIO (EVIO) and Gran Tierra Energy (GTE).

Organigram trades on the NASDAQ under the ticker symbol "OGI."

Organigram's stock is owned by a variety of institutional and retail investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (0.81%), Intact Investment Management Inc. (0.42%), Renaissance Technologies LLC (0.35%), Dimensional Fund Advisors LP (0.31%), Swiss National Bank (0.21%) and Baader Bank Aktiengesellschaft (0.18%).

Shares of OGI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OGI stock can currently be purchased for approximately $0.64.

Organigram (NASDAQ:OGI) has a market capitalization of $200.88 million and generates $111.27 million in revenue each year. The company earns $-11,230,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis.

The company employs 841 workers across the globe.

Organigram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The official website for the company is www.organigram.ca. The company can be reached via phone at (844) 644-4726.